Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factorial, Multicentric, Randomized Clinical Trial of Remdesivir and Immunotherapy in Combination With Dexamethasone for Moderate COVID-19 (the AMMURAVID Trial)

Next Previous
Trial Profile

Factorial, Multicentric, Randomized Clinical Trial of Remdesivir and Immunotherapy in Combination With Dexamethasone for Moderate COVID-19 (the AMMURAVID Trial)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 06 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Canakinumab (Primary) ; Dexamethasone (Primary) ; Hydroxychloroquine (Primary) ; Methylprednisolone sodium succinate (Primary) ; Sarilumab (Primary) ; Siltuximab (Primary) ; Tocilizumab (Primary)
  • Indications COVID 2019 infections; Pneumonia; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms AMMURAVID

Most Recent Events

  • 04 Feb 2024 Status changed from not yet recruiting to discontinued.
  • 30 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top